Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA
- 25 September 2013
- journal article
- research article
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 142 (7) , 1459-1466
Abstract
The impact of hepatitis C virus infection (HCI), the most common bloodborne virus infection in the USA, on outcome of active tuberculosis (TB) treatment is largely unknown. We aimed to describe characteristics of TB patients with hepatitis C virus infection (TB-HCI) in King County, Washington, including TB treatment duration and outcome. We reviewed 1510 records of patients treated for active TB at the Public Health – Seattle & King County Tuberculosis Control Program between 2000 and 2010, and identified 53 with HCI. Advanced age, being born in the USA, HIV infection, homelessness and injection drug use were independently associated with HCI in TB cases. Independent factors associated with increased treatment duration included HIV infection, excess alcohol use, extrapulmonary TB, and any drug-resistant TB disease. Our findings suggest that TB-HCI patients can be successfully treated for active TB without extending treatment duration.Keywords
This publication has 19 references indexed in Scilit:
- Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- Treatment Duration for Patients with Drug-Resistant Tuberculosis, United StatesEmerging Infectious Diseases, 2012
- Hepatitis C virus infection in USA: an estimate of true prevalenceLiver International, 2011
- Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and TuberculosisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis CasesAmerican Journal of Therapeutics, 2010
- Hepatitis C Virus Infection and Hepatotoxicity During Antituberculosis ChemotherapyChest, 2007
- An Official ATS Statement: Hepatotoxicity of Antituberculosis TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002Annals of Internal Medicine, 2006
- Global Burden of Disease (GBD) for Hepatitis CThe Journal of Clinical Pharmacology, 2004
- Antituberculosis Drug–induced Hepatotoxicity: The Role of Hepatitis C Virus and the Human Immunodeficiency VirusAmerican Journal of Respiratory and Critical Care Medicine, 1998